Meet us at

BIO-Europe Spring 2016

April 4 - 6, 2016

Stockholm, Sweden

Latest news

Prosper Menière Society’s Gold Medal Award

 March 11, 2012 - STOCKHOLM, Sweden. Synphora AB announced today that Professor Helge Rask-Andersen, Uppsala University Hospital, Uppsala, Sweden has been awarded the Prosper Menière Society’s Gold Medal Award for furthering the goals of the Prosper Menière Society through research excellence, scientific innovation and far-reaching contributions to the investigation of inner ear research. Helge Rask-Andersen was nominated and chosen unanimously by the members of the Society.

The Award was presented to Helge Rask-Andersen at the 15th International Symposium and Workshops on Inner Ear Medicine and Surgery held in Austria, March 10 – 15, 2012.

“Professor Helge Rask-Andersen has laid the scientific foundation for the novel and promising  therapeutic approach for the treatment of Menière’s disease currently under development by Synphora”, said Fredrik Henell, CEO of Synphora AB. “Professor Helge Rask-Andersen’s Award serves to confirm the immense scientific value that he has contributed to Synphora  We are delighted to have him on our Scientific Advisory Board.”

The Prosper Menière Society is named after the French otolaryngologist Prosper Menière (1799 – 1862) who was the first to describe a triad of symptoms defining Menière’s disease. The Scoiety was founded in 1981 by the International Menière’s Disease Research Institute (IMDRI) of the Colorado Otologic Research Center (CORC). Today it resides at the Univesity  of Arkansas for Medical Sciences. The primary goal of the Society is to promote the academic dissemination and discussion of clinical research data on Menière’s disease and all aspects of inner ear dysfunction, pathophysiology, diagnosis and treatment

About Synphora

Synphora is a biopharmaceutical company focusing on the development of pharmacological treatments for diseases of the inner ear, in particular

  • Menière’s disease
  • Noise-induced tinnitus

The Company is about to initiate a phase IIB clinical trial in Menière’s disease.

The current strategy is to build on the therapeutic principle of administrating a prostaglandin Freceptor agonist to the eye. This treatment has been successfully established and is in worldwide clinical use for the treatment of glaucoma for the last 25 years.

Menière’s disease is typically associated with a retention of fluid in the membranous labyrinth of the inner ear. This is in analogy with glaucoma, where a buildup of intra-ocular fluid causes an elevation of intra-ocular pressure and as a consequence damage to the optic nerve. This is why Menière’s disease is often referred to as “glaucoma of the ear”.

There is a large body of experimental work suggesting that prostaglandin F receptor agonists are associated with a neuroprotective effect which is distinctly different and additional to their ability to lower the intra-ocular pressure by enhancing the drainage of fluid from the eye. This effect may work equally well for the treatment of noise-induced tinnitus.

For further information, please contact:

Fredrik Henell
CEO
Synphora AB

Phone: + 46 70 325 38 47
Email: fredrik.henell@synphora.com

Download as PDF

2013-10-16

First patient dosed in Synphora’s Phase II/III study of latanoprost as a treatment for Menière’s disease

October 16, 2013 - STOCKHOLM, Sweden. Synphora AB announced today that dosing has been initiated in a randomized, multicenter, double-blind Phase II/III study of latanoprost as a treatment for Menière’s disease. A total of 120 patients will be included in the trial. 

2012-03-11

Prosper Menière Society’s Gold Medal Award

March 11, 2012  - STOCKHOLM, Sweden. Synphora AB announced today that Professor Helge Rask-Andersen, Uppsala University Hospital, Uppsala, Sweden has been awarded the Prosper Menière Society’s Gold Medal Award for 2012.

2011-10-24

Synphora completes equity financing and William Gunnarsson joins the Board

October 24, 2011 - STOCKHOLM, Sweden. Synphora AB announced today that it has successfully completed an equity issue to fund the further development of its novel treatments for Menière’s disease and noise-induced tinnitus. There is currently no effective treatment for neither of these diseases.

William Gunnarsson representing BWG Holding, the lead investor in this financing round, will also join the Board of Directors of the Company.

Hemsida av Webbyrå KA Stockholm